Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of ibrutinib in pediatric chronic graft versus host disease
2017-004558-41Phase 2Active
- Sponsor
- Pharmacyclics
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of ibrutinib in chronic graft-versus-host disease (cGVHD), sponsored by Pharmacyclics. Primary endpoint: Primary PK endpoint (Part A). Started Nov 2018; status: active.
02
Drugs
ibrutinib
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on 2017-004558-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004558-41.